Findings from this study showed that GPD treatment in P301S mice with a dose of (4 mg/kg) showed marked decrease in levels of NF-kB and TNF-α when compared with WT group confirming the GPD ability to decrease initiation and progression of tauopathies and its related neuroinflammation. The gene discussed is NFKB1; the disease is tauopathy.